U.S. pharmaceutical companies expanding distribution into the European Union consistently underestimate the gap between U.S. distribution requirements and EU Good Distribution Practice (GDP) requirements. The result: compliance gaps that emerge during inspections, market access delays, and operational changes that have to be made under regulatory pressure rather than through deliberate planning. This article documents the major divergences and identifies what U.S. companies most commonly miss.
The structural difference
U.S. distribution regulation operates primarily through the FDA's Drug Supply Chain Security Act (DSCSA) and 21 CFR Part 211 requirements for pharmaceutical handling. The framework focuses on supply chain security (preventing counterfeit and diverted product) and basic quality management.
EU GDP, codified primarily in 2013/C 343/01 and detailed in subsequent guidance, takes a more comprehensive approach. It addresses not just supply chain security but the entire quality management system for distribution operations, including personnel qualification, premises and equipment, documentation, operations, complaints handling, and self-inspection.
The structural difference: U.S. regulation establishes minimum requirements; EU GDP establishes a comprehensive quality framework. Companies operating to U.S. standards often don't meet EU expectations even when they comply with all U.S. requirements.
The Qualified Person requirement
One of the most-significant differences. EU GDP requires distribution operations to designate a Responsible Person (RP) — a qualified individual responsible for ensuring GDP compliance. The RP must have specific qualifications and experience, must be physically located in the EU, and has personal regulatory accountability.
The U.S. has no equivalent requirement. U.S. companies that distribute into the EU often appoint an RP as a checkbox without understanding the role's scope. When inspections occur, the RP's actual involvement in operations becomes evident; companies whose RP is nominal rather than substantive face significant findings.
What U.S. companies miss: the RP isn't a paperwork role. The RP must be substantively involved in quality decisions, must approve key operations, and must have authority to halt operations that violate GDP. Appointing a junior employee or external consultant as RP without the necessary authority is a common compliance gap.
Documentation requirements
U.S. distribution requires documentation of certain activities; EU GDP requires comprehensive documented procedures for essentially all operations.
The required documentation set includes:
- Standard Operating Procedures (SOPs) covering all GDP-relevant activities
- Personnel training records demonstrating competence in assigned tasks
- Equipment qualification documentation
- Calibration records for monitoring equipment
- Complete temperature monitoring records for shipments
- Deviation documentation with root cause analysis and CAPA
- Self-inspection records and findings
- Vendor qualification documentation
The depth of documentation required exceeds typical U.S. distribution practice. U.S. companies often have some of these documents but not all, and the existing documents may not meet EU expectations for completeness or rigor.
Vendor qualification
EU GDP requires distributors to qualify their suppliers and customers. The qualification process verifies that suppliers are licensed, that the products they supply are legitimate, and that customers are authorized to receive the products.
For commercial distribution, this means maintaining documentation that confirms each supplier's wholesale distribution authorization (WDA), each customer's authorization to purchase, and the verification activities performed.
U.S. distribution has lighter requirements for vendor qualification. Companies often don't maintain the documentation that EU GDP expects. The gap appears immediately during EU inspections.
Premises and equipment
EU GDP includes specific requirements for distribution premises:
- Adequate area for storage with appropriate environmental controls
- Segregation of products in different statuses (released, quarantined, returned, recalled)
- Pest control measures
- Security to prevent unauthorized access
- Equipment qualification for any equipment affecting product quality (refrigerators, freezers, monitoring systems)
Most U.S. distribution facilities meet these requirements substantively but may not have documentation demonstrating compliance. EU inspectors expect to see the documentation, not just the practices.
Temperature monitoring
EU GDP requires comprehensive temperature monitoring for cold chain shipments and storage. Specific requirements:
- Calibrated monitoring equipment with documented calibration history
- Continuous monitoring throughout the supply chain
- Documented review of temperature data after each shipment
- Defined procedures for handling excursions
- Stability data supporting product disposition decisions after excursions
U.S. cold chain practice typically meets these requirements operationally. The documentation rigor expected by EU inspectors often exceeds what U.S. operations maintain.
Self-inspection
EU GDP requires distributors to conduct periodic self-inspections (internal audits) of their GDP compliance. The inspections must be documented, findings must be addressed through CAPA processes, and the self-inspection program itself is subject to inspection.
U.S. distribution has no equivalent requirement. Companies often don't conduct internal audits at the depth EU expects, and when inspections occur, the absence of self-inspection documentation is a significant finding.
Returned product handling
EU GDP has specific requirements for returned product. Returns can only be returned to saleable stock under specific conditions, including verification of storage conditions during the return period and approval by the Responsible Person.
U.S. practice is more variable. Companies that allow returned product back into saleable stock without the documentation EU requires face compliance gaps that emerge during inspections.
The most-common compliance gaps
Across U.S. companies expanding into EU distribution, the most-frequent compliance gaps:
- Inadequate Responsible Person involvement. RP appointed but not substantively engaged in operations.
- Documentation gaps. Operations conducted properly but documentation doesn't demonstrate compliance.
- Vendor qualification incomplete. Trading partners qualified informally without documented verification.
- Self-inspection absent or weak. No internal audit program, or audits that don't identify findings consistently.
- Temperature monitoring documentation incomplete. Monitoring conducted but post-shipment review documentation missing.
- SOPs not aligned with actual operations. Procedures written but operations diverge from them.
Each of these is addressable with focused work. The total scope of changes required for full GDP compliance is substantial; the work needs months of dedicated effort, not weeks.
The implementation approach
For U.S. companies preparing for EU GDP compliance, the recommended sequence:
- Conduct a gap analysis against EU GDP requirements with someone experienced in EU compliance
- Appoint a substantively-engaged Responsible Person with appropriate authority
- Develop or update SOPs to address GDP requirements comprehensively
- Implement self-inspection program with documented findings and CAPA
- Strengthen vendor qualification documentation
- Build temperature monitoring documentation rigor
- Conduct mock inspection before actual operations begin
This work typically takes 6-12 months for a company without prior EU experience. Compressing the timeline produces inadequate preparation that emerges during actual inspections.
The broader pattern
The U.S.-EU divergence in pharmaceutical distribution regulation reflects a broader difference in regulatory philosophy. U.S. regulation tends toward specific requirements with clear compliance criteria; EU regulation tends toward comprehensive quality systems with judgment-based assessment.
Companies operating successfully in both jurisdictions develop frameworks that meet both standards. The investment is significant, but the alternative — repeatedly addressing compliance gaps during inspections — is more expensive and more disruptive over time.
The takeaway
The gap between U.S. distribution practice and EU GDP requirements is larger than U.S. companies typically appreciate. Comprehensive preparation before EU operations begin is much less expensive than addressing gaps after inspections identify them.
For companies considering EU expansion, the regulatory analysis should begin early, the investment should be planned realistically, and the operational changes should be made through deliberate implementation rather than reactive response to compliance findings.
Source notes
Regulatory analysis draws on EU Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01) and subsequent EMA guidance. U.S. requirements reference 21 CFR Parts 211 and 600 and DSCSA implementation as of 2025. Inspection findings patterns based on aggregated industry reports from PIC/S inspection summaries 2023-2025.
